Never too old to fight breast cancer: A case report

Research output: Contribution to journalArticle

Abstract

RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival. Elderly patients are frequently undertreated because of concerns about their age, performance status, and comorbidities. Here, we report a case of an octogenarian patient treated with T-DM1 with brilliant results.

PATIENT CONCERNS: An 87 years old woman affected with HER-2 positive breast cancer presented progression of disease with lymph node and skin metastases after 3 lines of chemoimmunotherapy.

DIAGNOSES: Breast cancer in elderly patient, lymph node, and skin metastases.

INTERVENTIONS: Chemoimmunotherapy (trastuzumab emtansine).

OUTCOME: Objective response of the disease and significant clinical benefit.

LESSONS: This case clearly suggests that age and comorbidities do not always represent an absolute contraindication to combined treatments.

Original languageEnglish
Pages (from-to)e9981
JournalMedicine
Volume97
Issue number9
DOIs
Publication statusPublished - Mar 2018

Fingerprint

Breast Neoplasms
Comorbidity
Lymph Nodes
Neoplasm Metastasis
erbB-1 Genes
Skin
Disease-Free Survival
Disease Progression
Drug Therapy
Neoplasms
Therapeutics

Keywords

  • Aged, 80 and over
  • Antineoplastic Agents, Immunological/therapeutic use
  • Breast Neoplasms/chemistry
  • Female
  • Humans
  • Lymph Nodes/pathology
  • Lymphatic Metastasis
  • Maytansine/analogs & derivatives
  • Receptor, ErbB-2/analysis
  • Skin Neoplasms/drug therapy
  • Trastuzumab/therapeutic use

Cite this

Never too old to fight breast cancer : A case report. / Zuradelli, Monica; Masci, Giovanna; Ferraro, Emanuela; Losurdo, Agnese; De Sanctis, Rita; Torrisi, Rosalba; Santoro, Armando.

In: Medicine, Vol. 97, No. 9, 03.2018, p. e9981.

Research output: Contribution to journalArticle

@article{21205bf41bd44ea596efa21bfe34de6a,
title = "Never too old to fight breast cancer: A case report",
abstract = "RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20{\%} of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival. Elderly patients are frequently undertreated because of concerns about their age, performance status, and comorbidities. Here, we report a case of an octogenarian patient treated with T-DM1 with brilliant results.PATIENT CONCERNS: An 87 years old woman affected with HER-2 positive breast cancer presented progression of disease with lymph node and skin metastases after 3 lines of chemoimmunotherapy.DIAGNOSES: Breast cancer in elderly patient, lymph node, and skin metastases.INTERVENTIONS: Chemoimmunotherapy (trastuzumab emtansine).OUTCOME: Objective response of the disease and significant clinical benefit.LESSONS: This case clearly suggests that age and comorbidities do not always represent an absolute contraindication to combined treatments.",
keywords = "Aged, 80 and over, Antineoplastic Agents, Immunological/therapeutic use, Breast Neoplasms/chemistry, Female, Humans, Lymph Nodes/pathology, Lymphatic Metastasis, Maytansine/analogs & derivatives, Receptor, ErbB-2/analysis, Skin Neoplasms/drug therapy, Trastuzumab/therapeutic use",
author = "Monica Zuradelli and Giovanna Masci and Emanuela Ferraro and Agnese Losurdo and {De Sanctis}, Rita and Rosalba Torrisi and Armando Santoro",
year = "2018",
month = "3",
doi = "10.1097/MD.0000000000009981",
language = "English",
volume = "97",
pages = "e9981",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Never too old to fight breast cancer

T2 - A case report

AU - Zuradelli, Monica

AU - Masci, Giovanna

AU - Ferraro, Emanuela

AU - Losurdo, Agnese

AU - De Sanctis, Rita

AU - Torrisi, Rosalba

AU - Santoro, Armando

PY - 2018/3

Y1 - 2018/3

N2 - RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival. Elderly patients are frequently undertreated because of concerns about their age, performance status, and comorbidities. Here, we report a case of an octogenarian patient treated with T-DM1 with brilliant results.PATIENT CONCERNS: An 87 years old woman affected with HER-2 positive breast cancer presented progression of disease with lymph node and skin metastases after 3 lines of chemoimmunotherapy.DIAGNOSES: Breast cancer in elderly patient, lymph node, and skin metastases.INTERVENTIONS: Chemoimmunotherapy (trastuzumab emtansine).OUTCOME: Objective response of the disease and significant clinical benefit.LESSONS: This case clearly suggests that age and comorbidities do not always represent an absolute contraindication to combined treatments.

AB - RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival. Elderly patients are frequently undertreated because of concerns about their age, performance status, and comorbidities. Here, we report a case of an octogenarian patient treated with T-DM1 with brilliant results.PATIENT CONCERNS: An 87 years old woman affected with HER-2 positive breast cancer presented progression of disease with lymph node and skin metastases after 3 lines of chemoimmunotherapy.DIAGNOSES: Breast cancer in elderly patient, lymph node, and skin metastases.INTERVENTIONS: Chemoimmunotherapy (trastuzumab emtansine).OUTCOME: Objective response of the disease and significant clinical benefit.LESSONS: This case clearly suggests that age and comorbidities do not always represent an absolute contraindication to combined treatments.

KW - Aged, 80 and over

KW - Antineoplastic Agents, Immunological/therapeutic use

KW - Breast Neoplasms/chemistry

KW - Female

KW - Humans

KW - Lymph Nodes/pathology

KW - Lymphatic Metastasis

KW - Maytansine/analogs & derivatives

KW - Receptor, ErbB-2/analysis

KW - Skin Neoplasms/drug therapy

KW - Trastuzumab/therapeutic use

U2 - 10.1097/MD.0000000000009981

DO - 10.1097/MD.0000000000009981

M3 - Article

C2 - 29489698

VL - 97

SP - e9981

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 9

ER -